The PennZone

International Collaboration Aims to Ensure More Equitable Access to Transformative Personalized Cancer Therapy

PHILADELPHIA, May 23, 2022 /PRNewswire/ -- Penn Medicine and Children's Hospital of Philadelphia (CHOP), who together pioneered the research and development of the world's first personalized cellular therapy for cancer — also known as CAR T cell therapy — have announced plans with Costa Rica's CCSS, or the Caja Costarricense de Seguro Social (Social Security Program), to facilitate CAR T research in Costa Rica. The effort is a step toward global equity in clinical research opportunities involving the use of CAR T cell therapies, which represent a leading-edge approach to cancer care not widely available across the world.

More on The PennZone

• RimbaMindaAI Officially Launches Version 3.0 Following Strategic Breakthrough in Malaysian Market Analysis
• Fed Rate Pause & Dow 50k: Irfan Zuyrel on Liquidity Shifts, Crypto Volatility, and the ASEAN Opportunity
• 20/20 Institute Launches Updated Vision Correction Procedures Page for Denver & Colorado Springs
• OneVizion Announces Next Phase of Growth as Brad Kitchens Joins Board of Directors
• New Children's Picture Book "Diwa of Mount Luntian" Focuses on Calm, Culture, and Connection for Today's Families

---

Show All News | Report Violation